Gain Therapeutics, Inc. (GANX)
NASDAQ: GANX · Real-Time Price · USD
1.776
-0.074 (-3.99%)
Aug 28, 2026, 12:53 PM EDT - Market open
Gain Therapeutics Employees
As of December 31, 2025, Gain Therapeutics had 21 total employees, including 20 full-time and 1 part-time employees. The number of employees decreased by 4 or -16.00% compared to the previous year.
Employees
21
Change (1Y)
-4
Growth (1Y)
-16.00%
Revenue / Employee
n/a
Profits / Employee
-$957,441
Market Cap
77.52M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 21 | -4 | -16.00% | 20 | 1 |
| Dec 31, 2024 | 25 | -7 | -21.88% | 23 | 2 |
| Dec 31, 2023 | 32 | 1 | 3.23% | 29 | 3 |
| Dec 31, 2022 | 31 | 2 | 6.90% | 28 | 3 |
| Dec 31, 2021 | 29 | 15 | 107.14% | 25 | 4 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Verrica Pharmaceuticals | 76 |
| Elicio Therapeutics | 33 |
| Cardiff Oncology | 31 |
| NeurAxis | 24 |
| Cingulate | 14 |
| Eloxx Pharmaceuticals | 10 |
| Alterity Therapeutics | 9 |
| Annovis Bio | 7 |
GANX News
- 3 days ago - Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewsWire
- 16 days ago - Gain Therapeutics Earnings release: Q2 2026 - Filings
- 16 days ago - Gain Therapeutics Quarterly report: Q2 2026 - Filings
- 17 days ago - Gain Therapeutics reports Q2 EPS (11c), consensus (15c) - TheFly
- 25 days ago - Gain Therapeutics Slides: Corporate presentation - Filings
- 6 weeks ago - Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update - GlobeNewsWire
- 2 months ago - Gain Therapeutics receives FDA clearance of GT-02287 IND application - TheFly
- 2 months ago - Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson's Disease - GlobeNewsWire